Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million - Vivoryon

▤ Summary

Vivoryon Therapeutics completed a private placement that raised EUR 5.1 million through the issuance of new shares. The company said the financing extends its cash runway well into Q3 2026. It plans to use the proceeds to advance varoglutamstat in chronic kidney disease and to support efforts to secure a strategic partnership. The company is also preparing for a planned Phase 2 study in diabetic kidney disease if additional funding is needed. This capital raise gives Vivoryon more flexibility as it continues clinical development and partnership discussions.

$ Funding

▦ Linked Companies